XML 36 R25.htm IDEA: XBRL DOCUMENT

REVENUE (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Total Revenue by Type and by U.S versus Rest of World

The following table presents details regarding the composition of the Company’s total revenue by product type and by geographical region, either U.S. or rest of world (“RoW”):


	Three Months Ended September 30,
	2025						2024
(in millions)	U.S.		RoW		Total		U.S.		RoW		Total
Hereditary Cancer	$	81.8	$	11.2	$	93.0	$	78.4	$	12.1	$	90.5
Tumor Profiling	26.7		2.8		29.5		26.5		5.1		31.6
Prenatal	44.5		—		44.5		43.4		0.1		43.5
Pharmacogenomics	38.7		—		38.7		47.7		—		47.7
Total revenue	$	191.7	$	14.0	$	205.7	$	196.0	$	17.3	$	213.3


	Nine months ended September 30,
	2025						2024
(in millions)	U.S.		RoW		Total		U.S.		RoW		Total
Hereditary Cancer	$	241.8	$	33.8	$	275.6	$	235.6	$	34.5	$	270.1
Tumor Profiling	81.0		9.2		90.2		77.1		18.0		95.1
Prenatal	141.2		0.2		141.4		131.7		0.5		132.2
Pharmacogenomics	107.5		—		107.5		129.6		—		129.6
Total revenue	$	571.5	$	43.2	$	614.7	$	574.0	$	53.0	$	627.0